Literatur
- 1
Aliverti S, Blasi F, Zanaboni A M. et al .
Duration of antibiotic therapy in hospitalized patients
with community-acquired pneumonia.
Eur Respir J.
2009, im Druck;
- 2
Ambrosino N, Vagheggini G.
Noninvasive positive
pressure ventilation in the acute care setting: where are we?.
Eur Respir J.
2008;
31
874-886
- 3
Anevlavis S, Bouros D.
Community acquired bacterial
pneumonia.
Expert Opin Pharmacother.
2010;
11
361-374
- 4
Aspa J, Rajas O, de Castro F R.
Pneumococcal antimicrobial resistance: therapeutic strategy
and management in community-acquired pneumonia.
Expert
Opin Pharmacother.
2008;
9
229-241
- 5
Barst R J, Gibbs J S, Ghofrani H A. et al .
Updated evidence-based treatment
algorithm in pulmonary arterial hypertension.
J Am Coll
Cardiol.
2009;
54
S78-S85
- 6
Beeh K M, Beier J.
Indacaterol, a novel inhaled,
once-daily, long-acting beta2-agonist for the treatment of obstructive
airways disease.
Adv Ther.
2009;
26
691-699
- 7
Beeh K M, Derom E, Kanniess F, Cameron R B, Higgins M W, van As A.
Indacaterol,
a novel inhaled ß2-agonist, provides sustained 24-h bronchodilation
in asthma.
Eur Respir J.
2007;
29
871-878
- 8
Boman G, Ludviksdottir D, Janson C. et al .
Exhaled nitric oxide and its relationship
to airway responsiveness and atopy in asthma.
Respir Med.
2008;
93
552-556
- 9
Calverley P M
A, Rabe K F, Goehring U -M, Kristiansen S, Fabbri L M, Martinez F J.
Roflumilast in symptomatic chronic obstructive pulmonary
disease: two randomised clinical trials.
Lancet.
2009;
374
685-694
- 10
Cazzola M, Matera M G.
Emerging inhaled bronchodilators:
an update.
Eur Respir J.
2009;
34
757-769
- 11
Chanez P, Burge P S, Dahl R. et al .
Aclidinium bromide provides long-acting
bronchodilation in patients with COPD.
Pulm Phamacol Therapeutics.
2010;
23
15-21
- 12
de Jongste J C, Carraro S, Hop W C, Baraldi E.
Daily telemonitoring
of exhaled nitric oxide and symptoms in the treatment of childhood
asthma.
Am J Respir Crit Care Med.
2009;
179
93-97
- 13
de Vries F, Setakis E, Zhang B, van Staa T P.
Long-acting
beta2-agonists in adult asthma and the pattern of risk of death
and severe asthma outcomes: a study with the General Practice Research
Database.
Eur Respir J.
2010, im Druck;
- 14
Dryden M, Hand K, Davey P.
Antibiotics for community-acquired pneumonia.
J Antimicrob
Chemother.
2009;
64
1123-1125
- 15
Dweik R A, Sorkness R L, Wenzel S. et al .
Use of exhaled nitric oxide measurement
to identify a reactiv, at-risk phenotype among patients with asthma.
Am J Respir Crit Care Med.
2010, im Druck;
- 16
Fabbri L M, Calverley P MA, Izquierdo-Alonso J L. et al .
Roflumilast in
moderate to severe chronic obstructive pulmonary disease treated
with longacting bronchodilators: two randomised trials.
Lancet.
2009;
374
695-703
- 17
Fabbri L M, Luppi F, Beghe B, Rabe K F.
Complex chronic comorbidities
of COPD.
Eur Respir J.
2008;
31
212
- 18
Galié N, Hoeper M M, Humpert M. et al .
Guidelines on diagnosis and treatment of
pulmonary aterial hypertension. The task force on diagnosis and
treatment of pulmonary arterial hypertension of the European Society
of Cardiology (ESC) and the European Respiratory Society (ERS),
endorsed by the International Society of Heart and Lung Transplantation
(ISHLT).
Eur Heart J.
2009;
30
2493-2537
- 19
Gavalda A, Miralpeix M, Ramos I. et al .
Characterization of aclidinium bromide,
a novel inhaled muscarinic antagonist, with long duration of action
and a favorabale pharmacological profile.
J Pharmacol
Exp Ther.
2009, im Druck;
- 20
Goeckenjan G, Sitter H, Thomas M. et al .
Prävention, Diagnostik, Therapie
und Nachsorge des Lungenkarzinoms. Interdiziplinäre S3-Leitlinie
der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin
und der Deutschen Krebsgesellschaft.
Pneumologie.
2010;
2
e1-e164
- 21
Hirsh V.
Systemic therapies in metastatic non-small-cell lung cancer
with emphasis on targeted therapies: the rational approach.
Curr
Oncol.
2010;
17
12-23
- 22
Höffken G, Lorenz J, Kern W. et
al .
Epidemiologie, Diagnostik, antimikrobielle Therapie
und Management von erwachsenen Patienten mit ambulant erworbenen
unteren Atemwegsinfektion sowie ambulant erworbener Pneumonie – Update
2009.
Pneumologie.
2009;
63
e1-e68
- 23
Höffken G, Lorenz J, Kern W. et
al .
Epidemiologie, Diagnostik, antimikrobielle Therapie
und Management von erwachsenen Patienten mit ambulant erworbenen
unteren Atemwegsinfektionen sowie ambulant erworbener Pneumonie – Update
2009. S3-Leitlinie der Paul-Ehrlich-Gesellschaft für Chemotherapie,
der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin,
der Deutschen Gesellschaft für Infektiologie und vom Kompetenznetzwerk
(CAPNETZ).
Pneumologie.
2009;
63
e1-e68
- 24
Jaeschke R, O’Byrne P M, Mejza F. et al .
The safety of long-acting ß-Agonists
among patients wiht asthma using inhaled corticosteroids. Systematic
review and metaanalysis.
Am J Respir Crit Care Med.
2008;
178
1009-1016
- 25
Joos G F, Schelfhout V J, Pauwels R A. et al .
Bronchodilatory
effects of aclidinium bromide, along-acting muscarinic antagonist in
COPD patients.
Respir Med.
2009, im Druck;
- 26
Lim W S, Baudouin S V, George R C. et al .
BTS guidelines for the management
of community acquired pneumonia in adults: update 2009.
Thorax.
2009;
64
iii1-iii55
- 27
Pearlman D S, Greos L, Laforce C, Orevillo C, Owen R, Higgins M W.
Bronchodilator
efficacy of indacaterol, a novel once-daily beta2-agonist, in patients
with persistent asthma.
Ann Allergy Asthma Immunol.
2008;
101
90-95
- 28
Petsky H L, Cates C J, Li A M, Kynaston J A, Turner C, Chang A B.
Tailored
interventions based on exhaled nitric oxide versus clinical symptoms
for asthma in children and adults.
Cochrane Database Syst
Rev.
2008;
2
CD006340
- 29
Rennard S I, Bantje T, Centanni S. et al .
A dose-ranging study of indacaterol in
obstructive airways disease, with a tiotropium comparison.
Respir
Med.
2008;
102
1033-1044
- 30
Rossi A, Maione P, Sacco P C, Ambrosio R, Falanga M, Gridelli C.
Vascular endothelial growth
factor receptoras target for advanced non-smallcell lung cancer
therapy.
Curr Drug Targets.
2010, im Druck;
- 31
Sears M R, Ottosson A, Radner F, Suissa S.
Long-acting ß-agonists:
a review of formoterol safety data from asthma clinical trials.
Eur Respir J.
2009;
33
21-32
- 32
Sterman D H, Mehta A C, Wood D E. et al .
A multicenter pilot study
of a bronchial valve for the treatment of severe emphysema.
Respiration.
2010;
79
222-233
- 33
Vosswinckel R, Reichenberger F, Gall H, Seeger W, Grimminger F, Ghofrani H A.
Therapie
der pulmonalarteriellen Hypertonie.
Internist.
2009;
50
1104-1109
Dr. med. Anja Häussermann
Robert-Koch-Klinik
Nikolai-Rumjanzew-Str.
100
04207 Leipzig
Email: anja.haeussermann@gmx.de
